Andere talen Genprex, Inc.

Aandelen

GNPX

US3724462037

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 06-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,614 ^USD	+7,13%		+14,15%	-71,59%

03/04	Genprex breidt klinische studiesites uit voor de Acclaim-3 klinische studie van Reqorsa Therapy in combinatie met Tecentriq voor de behandeling van kleincellige longkanker	CI
02/04	Genprex, Inc. Medewerkers publiceren positieve preklinische gegevens over NPRL2-gentherapie met Oncoprex® toedieningssysteem	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting	10/04
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System	03/04
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer	03/04
Genprex, Inc. Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System	02/04
Genprex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Genprex Closes $6.5 Million Registered Direct Offering of Shares, Accompanying Warrants	22/03
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules	20/03
Genprex Launches $6.5 Million Securities Offering; Shares Fall	19/03
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers	13/03
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers	12/03
Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers	12/03
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting	07/03
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators	08/02
Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators	07/02
Genprex to Present at Upcoming BIO CEO and Investor Conference	07/02
Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer	05/02
Genprex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
North American Morning Briefing : Investors Weigh -2-	10/11
Genprex to Present at BIO-Europe 2023 Conference	02/11
AACR-NCI-EORTC International Conference 2023 – Completion of Acclaim-1 Dose Escalation: Recommended Phase 2 Dose of Quaratusugene Ozeplasmid Gene Therapy and Osimertinib	13-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Genprex, Inc.

Aandelen

GNPX

US3724462037

Andere talen

Filters